Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

James M. Metz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-1192-8506; OpenAlex author ID A5071888692. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. First author DOI 10.1002/cncr.35936↗
  2. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.35058↗
  3. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
  4. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  5. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.03.04↗
  6. Survivorship after treatment of pancreatic cancer: insights via an Internet-based survivorship care plan tool. Co-author DOI 10.21037/jgo.2017.08.07↗
  7. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… First author DOI 10.1007/s00280-013-2147-4↗
  8. Feasibility of electromagnetic transponder use to monitor inter- and intrafractional motion in locally advanced pancreatic cancer patients. Last author DOI 10.1016/j.ijrobp.2011.07.025↗
  9. Trends in the use of postoperative radiation therapy in patients with localized resectable pancreatic cancer. Last author DOI 10.1097/coc.0b013e31822dfd3c↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Peter Plastaras · 7 shared papers, 2012–2025 · strength 0.68
  2. Edgar Ben‐Josef · 5 shared papers, 2017–2025 · strength 0.61
  3. Mark H. O’Hara · 3 shared papers, 2018–2025 · strength 0.37
  4. Charles M. Vollmer · 2 shared papers, 2018–2025 · strength 0.27
  5. Thomas Benjamin Karasic · 1 shared paper, 2025 · strength 0.21
  6. Andre A. Konski · 1 shared paper, 2025 · strength 0.21
  7. Uri Amit · 1 shared paper, 2025 · strength 0.21
  8. Erica L. Carpenter · 1 shared paper, 2025 · strength 0.21
  9. Kim A. Reiss-Binder · 1 shared paper, 2025 · strength 0.21
  10. Jeffrey A. Drebin · 3 shared papers, 2013–2021 · strength 0.20
  11. Emily J. Anstadt · 1 shared paper, 2024 · strength 0.18
  12. Nikhil Yegya‐Raman · 1 shared paper, 2024 · strength 0.18
  13. Jacob Ezra Shabason · 2 shared papers, 2018–2021 · strength 0.17
  14. Kim A. Reiss · 2 shared papers, 2018–2021 · strength 0.17
  15. Adham Sean Bear · 1 shared paper, 2021 · strength 0.11
  16. William Tristram Arscott · 1 shared paper, 2021 · strength 0.11
  17. Stuti G. Shroff · 1 shared paper, 2021 · strength 0.11
  18. Peter James O'Dwyer · 2 shared papers, 2013–2018 · strength 0.09
  19. Christine E. Hill‐Kayser · 1 shared paper, 2017 · strength 0.08
  20. Melissa A. Frick · 1 shared paper, 2017 · strength 0.08
  21. Eric T. Shinohara · 2 shared papers, 2012 · strength 0.07
  22. Pamela J. Boimel · 1 shared paper, 2017 · strength 0.06
  23. Nirag Chandrakant Jhala · 1 shared paper, 2018 · strength 0.06
  24. Davendra P. S. Sohal · 1 shared paper, 2013 · strength 0.03
  25. Weijing Sun · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.